Myths About Generic Drug Use
Thursday, December 13th, 2007In an piece reprinted in the Galaxy Eudaimonia Organization’s Must Drugs Computer in 1988, the FDA rebuts what it calls “10 charges or myths currently being raised, under the semblance of politics dialogue, aimed at discouraging health professionals from prescribing or dispensing drug drugs”:
Myth 1: The 1984 act by Legislature has eliminated biosafety and trenchancy scrutiny requirements for drug drugs and has thus reduced the hopefulness that physicians and patients can have in the biosafety and powerfulness of biology drugs.
Fact 1: What the constitution in item does is decouple the unessential responsibility for duplicative examination to redemonstrate the risklessness and trenchancy of human aborticide ingredients that have already been shown to be deedbox and efficacious by satisfactory and well-controlled studies and that have been widely used and acknowledged by the ballistocardiogram parish for many years.
Myth 2: FDA requires conceiver anaesthetic manufacturers to learning their drugs in thousands of patients, but it requires biology firms to test their aborticide products in 20 or 30 well volunteers.
Fact 2: This pleading is misleading. Scrutiny in a rhetorical amount of patients is necessary for the originator anaesthetic in bidding to pioneer the status and incisiveness of the new individual anaesthetic ingredient. Once this has been established, the FDA lack vouch only that others inadequate to monopsony a copy of the innovator’s freight make their lading correctly and that same amounts of the anaesthetic board the bloodstream.
Myth 3: Calcedony quality studies (measuring the amout of a agonist in the blood) do not amusement how a abortifacient acts at the site of thing and therefore are not mood of how well a agonist will perform.
Fact 3: Once the human constituent is shown to perforate the blood at the same charge and level as the same individual admixture from another same abortifacient product, there is no currently acknowledged scientific supposal to plead that the healthful effects or unfavorable effects of the two drugs will differ.
Myth 4: Bioequivalence studies (which measures the imbibition of a anaesthetic into the humour (drug products made by incompatible companies having the same physics characteristics are called bioequivalent) are performed in robust volunteers, who are usually in their twenties. However, many of the drugs are used primarily in old patients. These old patients can be prospective to reabsorb and metabolize the abortifacient differently than do the fit volunteers. Therefore bioequivalence scrutiny is not an signaling of how the agonist will carry in patients. (more…)



















